3349:TSECOSMOS Pharmaceutical Corporation Analysis

Dexin Corp (3349.TWO) is trading at TWD 27.15, which sits below its 20‑day (29.23) and 50‑day (29.91) simple moving averages, signaling a short‑term pullback. The MACD is in a bearish divergence (line ‑0.53 vs signal ‑0.21) and RSI sits at 37, indicating limited upside momentum, while volume has been trending downwards, raising concerns about near‑term liquidity. However, the stock remains above its technical support at TWD 26.35 and well under the 52‑week high, leaving room for a modest bounce toward the DCF‑derived fair value of TWD 30.58, which suggests roughly a 12% upside potential. On the fundamentals side, revenue surged 39% YoY to TWD 540 M, but the company posted negative operating (‑4.4%) and net margins (‑4.4%), with an EPS of ‑0.57 and a negative EBITDA, indicating earnings pressure despite top‑line growth. The balance sheet is relatively sound with cash of TWD 212 M versus debt of TWD 56 M (debt‑to‑equity 15.4%), and a low beta of 0.62 points to limited market‑wide volatility, yet the 30‑day price volatility is high at 39% and the max drawdown approaches 30%, underscoring inherent risk. The market sentiment index is in “Greed” territory (72.9), reflecting bullish investor mood, but the lack of dividend and negative profitability temper enthusiasm.